RecruitingPhase 4NCT06970080

Therapeutic Relevance of Abnormal Airway Morphology in Asthma

Therapeutic Relevance of Abnormal Airway Morphology in Asthma: A Path to Optimized Management and Drug Development (AirPATH Study)


Sponsor

McMaster University

Enrollment

242 participants

Start Date

Jun 2, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Most individuals with asthma can effectively manage their symptoms and maintain normal lung function using inhaled medications, unfortunately, there is a subset of asthma sufferers whose symptoms, lung function, and risk of asthma attacks remain unimproved despite conventional inhaled medications. There could be several reasons for this. One possibility is that inhaled medications fail to reach the intended areas within the lungs, due to structural abnormalities within the airways themselves. Much like road conditions or closures can impede the speed and efficiency of vehicle travel, factors such as airway narrowing or mucus blockages, which are common in asthma, can obstruct the passage of inhaled medications through the airways. Our team has now optimized advanced medical imaging techniques, including magnetic resonance imaging (MRI) and computed tomography (CT), required to investigate this. This study will use these imaging methods to visually assess and measure individual patients' airways and determine whether abnormal airway structures impact how well they respond to inhaled and orally delivered medications. We anticipate finding that abnormal airway structures make inhaled medications less effective, but that they do not affect the response to oral medications.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating how abnormal airway shape and structure in people with asthma affects symptoms and treatment response — using advanced imaging to understand why some people with asthma respond better to certain inhalers than others. **You may be eligible if...** - You are 18 or older - You have been diagnosed with asthma by a respiratory specialist - You have evidence of airway sensitivity on testing (methacholine challenge or bronchodilator reversibility test) - You are willing and able to follow the study protocol **You may NOT be eligible if...** - You are a current smoker, or have smoked significantly in the past - You have a significant lung disease other than asthma (such as COPD or bronchiectasis) - You have had a respiratory infection or asthma flare-up in the past 4 weeks - You are pregnant or breastfeeding - You have contraindications to the imaging or lung function tests used Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGInhaled corticosteroid (ICS)

In Phase I, participants will receive additional same dose of extra-fine particle ICS (i.e., their ICS would be doubled) for 12-weeks.

DRUGOral Corticosteroid (OCS)

In phase II, participants will receive add-on oral prednisone (30mg/day) for one-week.


Locations(2)

St. Joseph's Healthcare Hamilton

Hamilton, Ontario, Canada

Western University

London, Ontario, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06970080


Related Trials